APA (7th ed.) Citation

Burger, M., Ehrend, E., Straßheimer, F., Cakmak, P., Krenzlin, H., Elleringmann, P., . . . Lee, S. (2026). REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA. Cytotherapy (Elsevier Inc.), 28(5), N.PAG. https://doi.org/10.1016/j.jcyt.2026.102167

Chicago Style (17th ed.) Citation

Burger, M., et al. "REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA." Cytotherapy (Elsevier Inc.) 28, no. 5 (2026): N.PAG. https://doi.org/10.1016/j.jcyt.2026.102167.

MLA (9th ed.) Citation

Burger, M., et al. "REPETITIVE INTRACRANIAL INJECTION OF NATURAL KILLER CELLS ENGINEERED WITH A HER2-TARGETED CHIMERIC ANTIGEN RECEPTOR ALONE AND IN COMBINATION WITH SYSTEMIC ANTI-PD-1 CHECKPOINT INHIBITION IN PATIENTS WITH RECURRENT GLIOBLASTOMA." Cytotherapy (Elsevier Inc.), vol. 28, no. 5, 2026, p. N.PAG, https://doi.org/10.1016/j.jcyt.2026.102167.